Information profile @ a Glance
- Bulk drug intermediates are the drugs used as raw materials for the
production of bulk drugs, or they can refer to a material produced
during synthesis of an API that must undergo further molecular change or
processing before it becomes an API.
- Drug intermediates are hygienically formulated using high grade raw
materials and they are used in the pharmaceutical and cosmetic industry
- The market is segmented into two main types, API intermediate, and
advanced intermediate.
- Advanced intermediate drugs are used to perform drug interaction
activity which formed in new chemical products. Capecitabine
intermediates, imatinib intermediates, lenalidomide intermediates,
pemetrexed intermediates, nilotinib intermediates, temozolamide
intermediates, gemcitabine intermediates, afatinib intermediates,
pazopanib intermediates, and ibrutinib intermediates are few examples of
drug intermediates.
- The global drug intermediate market is segmented into pharmaceutical
industry, biotechnology industry, and chemical industry
- A significant proportion of KSMs used by Indian pharmaceutical
companies are sourced from China, with a much smaller share coming from
Indian and European sources
- Some 48 active pharmaceutical ingredients (APIs) vital to the pharma
supply chain are sourced from the central province of Hubei. And
approximately 70% of APIs from China are shipped to India to produce
generics, of which around 40% are then shipped to the United States. In
fact, the European Fine Chemicals Group (EFCG) estimates that upward of
80% of chemicals used to make drugs sold in Europe now originate from
China and India.
- China accounts for 13% of all manufacturing sites of API for the US
market, following the US (28%), EU (26%) and India (18%), according to
agency data
- There are several types of intermediates used in pharma such as bulk
drug intermediates, veterinary drug intermediates and pharmaceutical
intermediates
- The Government of India has approved a scheme called the Production
Linked
Incentive (PLI) Scheme for promotion of domestic manufacturing of
critical Key
Starting Materials (KSMs) I Drug Intermediates (DIs) / Active
Pharmaceutical Ingredients (APIs) in India
- The objective of the Scheme is to attain self-reliance and reduce
import
dependence in critical KSMs/DlsIAPls. Under the Scheme, financial
incentives
shall be given based on threshold investment and domestic sales made by
selected applicant for the eligible products.
|
Basics
- Government Scheme of
support
- Production linked Incentive scheme
- Guidelines for the Production
Linked Incentive Scheme
Active
Pharmaceutical Ingredients
- API starting materials
- Starting Materials
Manufacturers
- Expansion Of Bulk Drug Intermediates And
Active Pharmaceutical Ingredients of company in Karnataka
- Proposed expansion plan
- API - Regulatory Control
- Starting
Materials For Active Substances
Technology Information
- Contract
Research & Manufacturing Services
- Services - R&D to
Commercial Manufacturing
- Project Management,
Basic & Detailed
Engineering Design and Safety-Regulatory
Services Company
Consultants & Support Organizations
- Central Drugs
Standard Control Organization
- Manufacturers Association
- University
- Custom synthesis company
- USA Food & Drug
Administration
- Consultant - Project reports
Drugs
- Drug Master File
- Dynamics of Drug Master Filings
- Excipient Master File
Guide
- Registration process of API in U.S and
Europe
- Amoxiclav Aristo Tablets
Project Information
- Proposed API & Drug Intermediates Manufacturing
Facility
- Proposed manufacturing plan of Bulk Drug
Intermediates - 90 Mt/month
- Bulk Drugs & Intermediates manufacturing Details
- Proposed project - Bulk drugs & Intermediates
- Bulk Drug Intermediates, Active Pharmaceutical
Ingredients, Specialty Chemicals and Biotech Products project
- Environment Impact Assessment Report - sample
- DPR - Project on Bulk drugs & Intermediates
Company
Information
- Company in Thane
- Company expansion plan
- Expansion Plan
- Company in China
Market Scenario
- India’s
Marketing Regulations of Drugs
- Domestic & Export market - India
- Pharmaceutical Sector -
Malaysia
Ordering Information |